Edition:
United States

Biomarin Pharmaceutical Inc (BMRN.OQ)

BMRN.OQ on NASDAQ Stock Exchange Global Select Market

88.00USD
26 May 2017
Change (% chg)

$0.67 (+0.77%)
Prev Close
$87.33
Open
$87.65
Day's High
$88.65
Day's Low
$87.65
Volume
303,740
Avg. Vol
399,390
52-wk High
$102.43
52-wk Low
$73.60

BMRN.OQ

Chart for BMRN.OQ

About

BioMarin Pharmaceutical Inc. is a biotechnology company. The Company develops and commercializes pharmaceuticals for various diseases and medical conditions. As of December 31, 2016, the Company's therapy portfolio consisted of five products, and multiple clinical and pre-clinical product candidates. Its commercial products... (more)

Overall

Beta: 1.87
Market Cap(Mil.): $15,238.21
Shares Outstanding(Mil.): 174.49
Dividend: --
Yield (%): --

Financials

  BMRN.OQ Industry Sector
P/E (TTM): -- 14.31 17.43
EPS (TTM): -3.41 -- --
ROI: -16.32 -7.26 -5.41
ROE: -22.19 -6.76 -4.69

BRIEF-Biomarin Q1 GAAP loss per share $0.09

* Q1 earnings per share view $-0.29 -- Thomson Reuters I/B/E/S

May 04 2017

Biomarin sets high price for rare pediatric brain disease drug

Biomarin Pharmaceuticals Inc said the annual price for its drug, which won U.S. approval on Thursday, to treat a rare and fatal type of pediatric brain disease is expected to be $486,000 after mandatory government discounts and rebates.

Apr 27 2017

UPDATE 2-Biomarin sets high price for rare pediatric brain disease drug

April 27 Biomarin Pharmaceuticals Inc said the annual price for its drug, which won U.S. approval on Thursday, to treat a rare and fatal type of pediatric brain disease is expected to be $486,000 after mandatory government discounts and rebates.

Apr 27 2017

BRIEF-Biomarin says Brineura U.S. annual price $486,000

* Biomarin Pharmaceuticals says expects to begin shipping just approved Brineura within 6 weeks

Apr 27 2017

U.S. FDA approves Biomarin's Batten disease drug

April 27 The United States Food and Drug Administration said on Thursday it had approved Biomarin Pharmaceutical Inc's drug to treat a type of Batten disease, a rare disorder that mainly affects the nervous system and is ultimately fatal.

Apr 27 2017

BRIEF-U.S. FDA says granted approval of Brineura to Biomarin Pharmaceutical

* Granted approval of Brineura to Biomarin Pharmaceutical Inc

Apr 27 2017

BRIEF-Biomarin announces Kuvan patent challenge settlement

* Biomarin announces Kuvan (sapropterin dihydrochloride) patent challenge settlement

Apr 13 2017

BRIEF-Biomarin reports Q4 GAAP loss per share $0.53

* Biomarin announces fourth quarter and full year 2016 financial results

Feb 23 2017

BRIEF-Jennison Associates Llc reports 5.4 pct passive stake in Biomarin Pharmaceutical

* Jennison Associates Llc reports 5.4 percent passive stake in Biomarin Pharmaceutical Inc as of Dec 31, 2016- sec filing Source text - http://bit.ly/2jIyNQd Further company coverage:

Feb 02 2017

BioMarin Pharma cites positive results for hemophilia treatment

Jan 8 BioMarin Pharmaceutical Inc announced on Sunday what it called "positive interim results" from its study of a gene therapy treatment for severe hemophilia.

Jan 08 2017

More From Around the Web

Competitors

  Price Chg
Johnson & Johnson (JNJ.N) $126.92 -0.61
Pfizer Inc. (PFE.N) $32.14 -0.02
Novartis AG (NOVN.S) CHF78.60 -0.50
Merck & Co., Inc. (MRK.N) $64.92 -0.12
Roche Holding Ltd. (ROG.S) CHF266.60 -0.60
Roche Holding Ltd. (RO.S) CHF267.75 +0.25
Abbott Laboratories (ABT.N) $44.71 +0.76
Bayer AG (BAYGn.DE) €116.70 -0.05
Bayer AG (BAYE.F) -- --
Sanofi SA (SASY.PA) €87.74 +0.43

Earnings vs. Estimates